Apogee Therapeutics, Inc. (APGE)
135.07
0.00 (0.00%)
USD |
NASDAQ |
Sep 11, 16:00
Apogee Therapeutics Enterprise Value : 9.310B for Sept. 11, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 11, 2026 | 9.310B |
| September 10, 2026 | 9.310B |
| September 09, 2026 | 9.310B |
| September 08, 2026 | 9.310B |
| September 04, 2026 | 9.310B |
| September 03, 2026 | 9.310B |
| September 02, 2026 | 9.310B |
| September 01, 2026 | 9.311B |
| August 31, 2026 | 9.311B |
| August 28, 2026 | 9.303B |
| August 27, 2026 | 9.302B |
| August 26, 2026 | 9.301B |
| August 25, 2026 | 9.294B |
| August 24, 2026 | 9.289B |
| August 21, 2026 | 9.286B |
| August 20, 2026 | 9.286B |
| August 19, 2026 | 9.283B |
| August 18, 2026 | 9.273B |
| August 17, 2026 | 9.274B |
| August 14, 2026 | 9.271B |
| August 13, 2026 | 9.264B |
| August 12, 2026 | 9.271B |
| August 11, 2026 | 9.282B |
| August 10, 2026 | 9.279B |
| August 07, 2026 | 9.293B |
| Date | Value |
|---|---|
| August 06, 2026 | 9.267B |
| August 05, 2026 | 9.247B |
| August 04, 2026 | 9.244B |
| August 03, 2026 | 9.238B |
| July 31, 2026 | 9.236B |
| July 30, 2026 | 9.252B |
| July 29, 2026 | 9.245B |
| July 28, 2026 | 9.242B |
| July 27, 2026 | 9.251B |
| July 24, 2026 | 9.251B |
| July 23, 2026 | 9.249B |
| July 22, 2026 | 9.236B |
| July 21, 2026 | 9.245B |
| July 20, 2026 | 9.241B |
| July 17, 2026 | 9.230B |
| July 16, 2026 | 9.236B |
| July 15, 2026 | 9.251B |
| July 14, 2026 | 9.227B |
| July 13, 2026 | 9.216B |
| July 10, 2026 | 9.203B |
| July 09, 2026 | 9.197B |
| July 08, 2026 | 9.173B |
| July 07, 2026 | 9.195B |
| July 06, 2026 | 9.192B |
| July 02, 2026 | 9.148B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 11.47B |
| Intellia Therapeutics, Inc. | 1.279B |
| Cogent Biosciences, Inc. | 5.251B |
| Revolution Medicines, Inc. | 40.91B |
| Moderna, Inc. | 53.59B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -85.85M |
| Total Expenses (Quarterly) | 85.85M |
| EPS Diluted (Quarterly) | -1.138 |
| Earnings Yield | -3.21% |
| Normalized Earnings Yield | -3.179 |